Trevi Therapeutics, Inc. financial data

Symbol
TRVI on Nasdaq
Industry
Pharmaceutical Preparations
Location
195 Church Street, 14 Th Floor, New Haven, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.13K % -4.44%
Debt-to-equity 11 % +2.15%
Return On Equity -63.3 % -133%
Return On Assets -57.1 % -133%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 76.9M shares +20.4%
Common Stock, Shares, Outstanding 75.5M shares +18.2%
Entity Public Float 106M USD +62%
Common Stock, Value, Issued 75K USD +17.2%
Weighted Average Number of Shares Outstanding, Basic 101M shares +1.97%
Weighted Average Number of Shares Outstanding, Diluted 101M shares +1.97%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 36.6M USD +70.2%
General and Administrative Expense 11.6M USD +14.6%
Operating Income (Loss) -48.2M USD -52.4%
Nonoperating Income (Expense) 3.87M USD -19.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.3M USD -65.4%
Income Tax Expense (Benefit) -29K USD +58.6%
Net Income (Loss) Attributable to Parent -44.3M USD -65.7%
Earnings Per Share, Basic -0.44 USD/shares -175%
Earnings Per Share, Diluted -0.44 USD/shares -175%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.1M USD -38.2%
Marketable Securities, Current 49.4M USD -21.4%
Other Assets, Current 667K USD -36.2%
Assets, Current 67.3M USD -28.3%
Property, Plant and Equipment, Net 174K USD -26.9%
Operating Lease, Right-of-Use Asset 973K USD -18.2%
Other Assets, Noncurrent 256K USD -13.8%
Assets 68.9M USD -28.1%
Accounts Payable, Current 1.61M USD +28.5%
Accrued Liabilities, Current 7.21M USD +99%
Liabilities, Current 9.12M USD +76.4%
Operating Lease, Liability, Noncurrent 816K USD -22.4%
Other Liabilities, Noncurrent 3K USD
Liabilities 9.94M USD +58.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 139K USD
Retained Earnings (Accumulated Deficit) -276M USD -19.2%
Stockholders' Equity Attributable to Parent 59M USD -34.2%
Liabilities and Equity 68.9M USD -28.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5M USD -27.7%
Net Cash Provided by (Used in) Financing Activities -28K USD +98.4%
Net Cash Provided by (Used in) Investing Activities -8.09M USD -190%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 75.5M shares +18.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.6M USD -1881%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.1M USD -38.2%
Deferred Tax Assets, Valuation Allowance 69.5M USD +13.8%
Deferred Tax Assets, Gross 70.1M USD +14.3%
Operating Lease, Liability 1.05M USD -14%
Depreciation 11K USD -15.4%
Payments to Acquire Property, Plant, and Equipment 57K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44M USD -64.6%
Lessee, Operating Lease, Liability, to be Paid 1.27M USD -18.8%
Property, Plant and Equipment, Gross 350K USD -11.4%
Operating Lease, Liability, Current 235K USD +37.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 368K USD +5.44%
Lessee, Operating Lease, Liability, to be Paid, Year One 349K USD +15.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 216K USD -36.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 377K USD +2.45%
Deferred Tax Assets, Operating Loss Carryforwards 50.3M USD +4.74%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 95K USD -74.8%
Operating Lease, Payments 285K USD +44.7%
Additional Paid in Capital 334M USD +4.15%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 35K USD +84.2%
Interest Expense 9K USD -99.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%